Skip to main content

Feminizing Procedures

Feminizing gender-affirming procedures span the breast / chest, genitalia, face, neck, and voice, each with distinct techniques, outcomes, and considerations. This page is organized by procedure category. For overview principles, see GAS Overview; for revisions, see Revision & Salvage GAS.

Breast Augmentation​

Breast augmentation is the most commonly performed feminizing GAS procedure, with 74% of transfeminine respondents in the U.S. Transgender Survey having undergone or desiring it.1 Timing should account for the patient's hormone goals, breast development, anatomy, and preferences; several years of hormonal development may change implant planning. See the adult eligibility framework below rather than treating one duration as mandatory for every patient.23

Key technical and outcome considerations:

  • Implant placement — subglandular or subpectoral, depending on body habitus and patient preference. Transfeminine patients have wider base widths, longer sternal-notch-to-nipple distances, and received larger implants in one retrospective comparison (median 500 mL vs 350 mL in cisgender women), often necessitating routine inframammary fold lowering.124
  • Complications — a meta-analysis of 1,864 transfeminine patients found pooled rates of capsular contracture 3.6%, hematoma / seroma 0.6%, and implant asymmetry / malposition 3.9%. Comparisons with historical cisgender cohorts found higher hematoma / seroma and malposition rates; this was not a randomized comparison.5
  • Satisfaction — High satisfaction was reported in a 36-patient operative series. In the Dutch survey, 773 of 3,073 invitees responded; 80% of respondents with augmentation were satisfied, while approximately one-third reported health complaints attributed to implants. Response selection limits population estimates.26
  • Reoperation rate — 5% due to complications in a separate series with 99 of 159 patients completing follow-up questionnaires at a median four years.7

Vaginoplasty​

Vaginoplasty is the most frequently performed feminizing genital surgery, with 87% of transfeminine respondents desiring it.1 The goal is to create an aesthetic and functional vulva and vaginal canal enabling receptive intercourse, erogenous clitoral sensation, and a downward-directed urine stream.8

Surgical Techniques​

  • Penile inversion vaginoplasty (PIV) — the gold standard. Penile skin is inverted to line the neovaginal canal, scrotal skin creates the labia, and the glans penis is used to construct a sensate clitoris via the dorsal neurovascular pedicle technique. Plan permanent hair removal with the surgeon for the skin that will line the canal or contact urine; the required area depends on the technique.193
  • Peritoneal pull-through vaginoplasty — increasingly used when penile skin is insufficient (e.g., prior circumcision, puberty blocker use). Laparoscopically harvested peritoneal flaps are combined with inverted penile skin. In a 52-patient series, mean depth at six months was 14.7 cm, about 96% reported satisfaction, and seven had complications. These observational findings do not guarantee physiologic lubrication or establish superiority to penile inversion.10
  • Intestinal (sigmoid) vaginoplasty — most commonly used after failed primary vaginoplasty; provides spontaneous mucus secretion but carries higher morbidity.9
  • Minimal-depth (vulvoplasty) — for patients who do not desire vaginal penetration; creates external female genitalia without a vaginal canal. Detailed in Non-Binary & Nullification.8

Complications​

Complication rates have been documented as high as 70%, though most are minor and do not alter long-term outcomes.8 In a 2018 single-surgeon cohort of 117 patients, the most common complications were granulation tissue (26%), intravaginal scarring (20%), and prolonged pain (20%).11 Major complications include rectovaginal fistula, rectal injury, and urethral / introital stenosis.8 Vaginal stenosis is an important complication across techniques. Difficulty maintaining dilation can contribute, but scarring, pain, pelvic-floor dysfunction, and operative or wound problems also require assessment.1213

Outcomes and Satisfaction​

Despite moderate complication risk, 94% of patients reported feeling positively about their genitals and would undergo the operation again; 71% reported resolution of gender dysphoria.11 A 2025 prospective study, with 48 complete respondents and a 55% response rate, reported postoperative improvement in depression (PHQ-9), anxiety (GAD-7), gender congruence, body image, and sexual function scores, with pain returning to baseline by 12 months.14

Robotic peritoneal-flap outcomes​

A 500-case retrospective series (published online in 2025; print 2026) provides larger follow-up data: 425 patients had at least one year of follow-up; 20 (4%) required procedural intervention for a complication and 61 (12%) underwent elective revision. Median self-reported vaginal depth at one year was 14.5 cm. This is useful counseling evidence from a specialist center, but it does not establish superiority over penile inversion because there was no concurrent randomized comparator.15

Postoperative Care​

  • Dilation — follow the operating team's long-term schedule. New pain, resistance, bleeding, or loss of depth warrants assessment; avoid forcing a dilator through resistance. Difficulty dilating should prompt support and investigation rather than assuming non-adherence.81316
  • Hygiene and discharge — care depends on whether the canal is skin-, peritoneum-, or bowel-lined. Persistent odor or discharge warrants examination for retained debris, granulation, infection, or fistula. Antiseptic douches and empiric antimicrobials are not a universal routine; follow the surgical team's tissue-specific regimen.817
  • Retained prostate — prostate cancer assessment remains relevant. When an examination is indicated, an endovaginal approach may improve access because the neovagina can separate the prostate from the rectum; examination route is not itself a screening program.1617
  • STI risk — evaluate the actual exposed sites and reconstructed tissue, using current infection guidance and an anatomy-specific examination.16

Facial Feminization Surgery (FFS)​

FFS is a group of craniomaxillofacial procedures that modify masculine facial features toward feminine proportions. It is often prioritized by patients because the face is the most publicly visible feature and directly affects social perception and safety.9 In a needs assessment, 65% of transfeminine respondents desired at least one FFS procedure.18

Common Procedures by Facial Third192021​

  • Upper third (49% of all FFS procedures) — forehead recontouring / frontal bone reduction (most common single procedure at 34.6%), brow lift, hairline advancement.
  • Middle third — rhinoplasty (12.8%), cheek augmentation, blepharoplasty.
  • Lower third — chin remodeling / genioplasty (12.2%), mandible / jaw reduction, lip lift, vermilion reconstruction.

Patients self-identify their brows (54.5%), jaws (33.3%), and chins (30.3%) as the most masculine aspects of their faces.22

Outcomes​

A prospective multicenter study of 66 patients demonstrated that the median Facial Feminization Outcome Score increased from 47.2 preoperatively to 80.6 at ≥ 6 months (p < 0.001), with significant improvements in mental health, social function, and quality of life.192223

Chondrolaryngoplasty (Tracheal Shave)​

This procedure reduces the anterior projection of the thyroid cartilage ("Adam's apple") and is frequently combined with other FFS procedures.2425 Desired by 45% of transfeminine individuals in one survey.18

  • Techniques — transcervical, transoral, or endoscopic-assisted approaches. Laryngoscopic-assisted techniques allow intraoperative vocal cord visualization to minimize injury risk.24
  • Complications — minimal; scarring and patient dissatisfaction with amount of cartilage removed are most common. Rare complications include dysphonia, hematoma, and laryngospasm. In a series of 32 patients, only one experienced temporary hoarseness that resolved within 6 weeks.2425

Voice Feminization​

Voice had the highest median dysphoria score (7/10) among the surveyed body regions in one online needs assessment.18 Options include voice therapy, surgery, or a combined approach.

  • Voice therapy (VT) — first-line; raises speaking fundamental frequency (SF0) with significant effect size (g = 0.86) and improved quality of life.26
  • Wendler glottoplasty — the preferred and most reliable surgical intervention; creates an anterior glottic web to shorten the vibrating length of the vocal folds. Effect size for SF0 improvement g = 1.21.2627
  • Feminization laryngoplasty — reduces the overall size of the larynx and pharynx, raising both fundamental and resonant frequencies. A pooled SF0 effect size of g = 3.05 was reported, but heterogeneous study methods prevent ranking procedures by these effect sizes.2628
  • Combined approach — integration of voice therapy and surgery is significantly more effective than therapy alone.27

Trade-offs include potential impact on vocal projection and risk of long-term dysphonia; postsurgical voice rehabilitation improves outcomes.27

Perioperative Hormone Management​

A key clinical question is whether to continue or discontinue estrogen perioperatively due to VTE concerns. See also the Gender-Affirming Hormone Therapy hub.

  • Observational evidence — among 407 primary vaginoplasty cases, the comparison included 212 continuing estrogen and 190 holding it; there were no VTE events in the continuing group and one in the holding group. In a separate 183-patient cohort, 138 continued estradiol and 45 temporarily held it; one VTE occurred in the continuing group. The latter abstract's printed 0.05% rate is inconsistent with its denominator, so the event count is more reliable. Risk-based selection and few events prevent an equivalence conclusion.2930
  • WPATH SOC8 recommends collaboration between hormone prescribers and surgeons. Assess formulation, personal VTE risk, procedure, prophylaxis, and the effects of hormone withdrawal; SOC8 does not mandate cessation or unconditional continuation for every operation.3
  • Practice variation persists — 51 of 150 invited surgeons responded to a survey; 43% reported stopping hormones for feminizing genital surgery. This describes practice and does not establish the best protocol.31
  • Transdermal estradiol may be preferred when VTE risk is elevated; much of the route-specific evidence is extrapolated from menopausal populations.32
  • VTE prophylaxis — tailor mechanical and pharmacologic prevention to the operation, mobility, bleeding risk, and patient factors. A surgeon survey or single case report does not establish a universal one-week regimen.33313

Eligibility and Timing Summary​

For adults, use the SOC8 eligibility framework: one competent assessment opinion is ordinarily sufficient if documentation is required. Hormones and their duration depend on the desired procedure and individual goals; they are not compulsory when unwanted or contraindicated. Gonadectomy and genital reconstruction warrant discussion of a stable hormone regimen, commonly six months when appropriate. Breast augmentation timing also depends on breast development. Older Endocrine Society guidance used a one-year genital-surgery interval; local documentation requirements may differ from current clinical guidance.343

Footnotes​

  1. Cronin B, Stockdale CK. "Health Care for Transgender and Gender Diverse Individuals." American College of Obstetricians and Gynecologists, 2021. ↩ ↩2 ↩3 ↩4

  2. Coon D, Lee E, Fischer B, Darrach H, Landford WN. "Breast Augmentation in the Transfemale Patient: Comprehensive Principles for Planning and Obtaining Ideal Results." Plast Reconstr Surg. 2020;145(6):1343–1353. doi:10.1097/PRS.0000000000006819 ↩ ↩2 ↩3

  3. Coleman E, Radix AE, Bouman WP, et al. "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8." Int J Transgend Health. 2022;23(Suppl 1):S1–S259. doi:10.1080/26895269.2022.2100644 ↩ ↩2 ↩3 ↩4 ↩5

  4. Torres Perez-Iglesias CA, Heyman A, Koh DJ, et al. "Technical and Clinical Differences Between Transgender and Cisgender Females Undergoing Breast Augmentation." Ann Plast Surg. 2023;91(5):534–539. doi:10.1097/SAP.0000000000003706 ↩

  5. Liu C, Shahid M, Yu Q, et al. "Complications Following Breast Augmentation in Transfeminine Individuals: A Systematic Review and Meta-Analysis." Plast Reconstr Surg. 2024;153(6):1240–1251. doi:10.1097/PRS.0000000000010691 ↩

  6. de Blok CJM, Staphorsius AS, Wiepjes CM, et al. "Frequency, Determinants, and Satisfaction of Breast Augmentation in Trans Women Receiving Hormone Treatment." J Sex Med. 2020;17(2):342–348. doi:10.1016/j.jsxm.2019.10.021 ↩

  7. Schoffer AK, Bittner AK, Hess J, Kimmig R, Hoffmann O. "Complications and Satisfaction in Transwomen Receiving Breast Augmentation: Short- and Long-Term Outcomes." Arch Gynecol Obstet. 2022;305(6):1517–1524. doi:10.1007/s00404-022-06603-3 ↩

  8. Morrison SD, Claes K, Morris MP, et al. "Principles and Outcomes of Gender-Affirming Vaginoplasty." Nat Rev Urol. 2023;20(5):308–322. doi:10.1038/s41585-022-00705-y ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  9. Wylie K, Knudson G, Khan SI, et al. "Serving Transgender People: Clinical Care Considerations and Service Delivery Models in Transgender Health." Lancet. 2016;388(10042):401–411. doi:10.1016/S0140-6736(16)00682-6 ↩ ↩2 ↩3

  10. Castanon CDG, Matic S, Bizic M, et al. "Laparoscopy Assisted Peritoneal Pull-Through Vaginoplasty in Transgender Women." Urology. 2022;166:301–302. doi:10.1016/j.urology.2022.05.001 ↩

  11. Massie JP, Morrison SD, Van Maasdam J, Satterwhite T. "Predictors of Patient Satisfaction and Postoperative Complications in Penile Inversion Vaginoplasty." Plast Reconstr Surg. 2018;141(6):911e–921e. doi:10.1097/PRS.0000000000004427 ↩ ↩2

  12. Horbach SE, Bouman MB, Smit JM, et al. "Outcome of Vaginoplasty in Male-to-Female Transgenders: A Systematic Review of Surgical Techniques." J Sex Med. 2015;12(6):1499–1512. doi:10.1111/jsm.12868 ↩

  13. Bishop MD, Morgan-Daniel J, Alappattu MJ. "Pain and Dysfunction Reported After Gender-Affirming Surgery: A Scoping Review." Phys Ther. 2023;103(7):pzad045. doi:10.1093/ptj/pzad045 ↩ ↩2

  14. Haley C, Roblee CV, Blasdel G, et al. "Gender-Affirming Vaginoplasty Improves Quality of Life in Transfeminine Individuals: A Single-Center Prospective Study." Ann Surg. 2025. doi:10.1097/SLA.0000000000006988 ↩

  15. Blasdel G, Hemal K, Dubach-Reinhold C, et al. "Gender-affirming Vaginoplasty Using Robotic Peritoneal Flap Method: Long-term Outcomes of 500 Cases." Ann Surg. 2026;283(6):1068–1074. Published online 2025. doi:10.1097/SLA.0000000000006621 ↩

  16. Jackson Q, Yedlinsky NT, Gray M. "Lifelong Care of Patients After Gender-Affirming Surgery." Am Fam Physician. 2024;109(6):560–565. ↩ ↩2 ↩3

  17. UCSF Gender Affirming Health Program. "Vaginoplasty procedures, complications and aftercare." 2016. Clinical guidance. ↩ ↩2

  18. Ziltzer RS, Lett E, Su-Genyk P, Chambers T, Moayer R. "Needs Assessment of Gender-Affirming Face, Neck, and Voice Procedures and the Role of Gender Dysphoria." Otolaryngol Head Neck Surg. 2023;169(4):906–916. doi:10.1002/ohn.329 ↩ ↩2 ↩3

  19. Siringo NV, Berman ZP, Boczar D, et al. "Techniques and Trends of Facial Feminization Surgery: A Systematic Review and Representative Case Report." Ann Plast Surg. 2022;88(6):704–711. doi:10.1097/SAP.0000000000002952 ↩ ↩2

  20. Ellis M, Choe J, Barnett SL, Chen K, Bradley JP. "Facial Feminization: Perioperative Care and Surgical Approaches." Plast Reconstr Surg. 2024;153(1):181e–193e. doi:10.1097/PRS.0000000000010886 ↩

  21. Azizi A, Sun A, Cheng LH, Hassan B, Liang F. "Facial Gender-Affirming Surgery: Upper and Middle Face Feminization." Clin Plast Surg. 2025;52(4):435–452. doi:10.1016/j.cps.2025.07.002 ↩

  22. Morrison SD, Capitán-Cañadas F, Sánchez-García A, et al. "Prospective Quality-of-Life Outcomes After Facial Feminization Surgery: An International Multicenter Study." Plast Reconstr Surg. 2020;145(6):1499–1509. doi:10.1097/PRS.0000000000006837 ↩ ↩2

  23. Morrison SD, Vyas KS, Motakef S, et al. "Facial Feminization: Systematic Review of the Literature." Plast Reconstr Surg. 2016;137(6):1759–1770. doi:10.1097/PRS.0000000000002171 ↩

  24. James AJ, Assi PE, Torres-Guzman RA, et al. "Optimizing Safety and Aesthetics in Facial Feminization: Laryngoscopic-Assisted Chondrolaryngoplasty (2019–2023)." J Craniofac Surg. 2024. doi:10.1097/SCS.0000000000010398 ↩ ↩2 ↩3

  25. Goslawski A, Spiegel JH. "Chondrolaryngoplasty." J Craniofac Surg. 2025;36(2):738–743. doi:10.1097/SCS.0000000000011134 ↩ ↩2

  26. Lanham K, Melnick BA, O'Connor MJ, et al. "Efficacy and Patient Satisfaction in Voice Feminization Procedures: A Systematic Review and Meta-Analysis." Otolaryngol Head Neck Surg. 2025;172(5):1521–1538. doi:10.1002/ohn.1173 ↩ ↩2 ↩3

  27. McBrinn S, Antoni C, Al Yaghchi C. "Current Approaches to Gender-Affirming Vocal Care." Curr Opin Otolaryngol Head Neck Surg. 2024;32(3):143–150. doi:10.1097/MOO.0000000000000967 ↩ ↩2 ↩3

  28. Thomas JP. "Feminization Laryngoplasty — A Comprehensive Approach to Reducing the Size of the Larynx and Pharynx." Otolaryngol Clin North Am. 2022;55(4):739–748. doi:10.1016/j.otc.2022.05.002 ↩

  29. Kozato A, Fox GWC, Yong PC, et al. "No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery." J Clin Endocrinol Metab. 2021;106(4):e1586–e1590. doi:10.1210/clinem/dgaa966 ↩

  30. Herndon J, Gupta N, Davidge-Pitts C, et al. "Genital Surgery Outcomes Using an Individualized Algorithm for Hormone Management in Transfeminine Individuals." J Clin Endocrinol Metab. 2024;109(11):2774–2783. doi:10.1210/clinem/dgae269 ↩

  31. Hung YC, Assi PE, Park BC, et al. "Patterns of Perioperative Hormone Therapy for Gender-Affirming Surgery." Ann Plast Surg. 2024;92(4):442–446. doi:10.1097/SAP.0000000000003820 ↩ ↩2

  32. Nolan BJ, Cheung AS. "Estradiol Therapy in the Perioperative Period: Implications for Transgender People Undergoing Feminizing Hormone Therapy." Yale J Biol Med. 2020;93(4):539–548. ↩

  33. Maharaj SK, Yu A, Singh A, Khanijow K. "Transforming Culture: Postoperative Venous Thromboembolism Prophylaxis in a Transgender Patient on Estrogen." J Gen Intern Med. 2025. doi:10.1007/s11606-025-09668-3 ↩

  34. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. "Endocrine Treatment of Gender-Dysphoric / Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi:10.1210/jc.2017-01658 ↩